These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 32597258)
1. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Jiang L; Ping L; Yan H; Yang X; He Q; Xu Z; Luo P Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):823-835. PubMed ID: 32597258 [TBL] [Abstract][Full Text] [Related]
2. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Roodhart JM; Langenberg MH; Witteveen E; Voest EE Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Tandle A; Libutti SK Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053 [TBL] [Abstract][Full Text] [Related]
5. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma. Stitzlein L; Rao P; Dudley R Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736 [TBL] [Abstract][Full Text] [Related]
6. Adverse effects of anticancer agents that target the VEGF pathway. Chen HX; Cleck JN Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909 [TBL] [Abstract][Full Text] [Related]
7. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eskens FA; Verweij J Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419 [TBL] [Abstract][Full Text] [Related]
8. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials. Zhang C; Tan C; Ding H; Xin T; Jiang Y Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661 [TBL] [Abstract][Full Text] [Related]
9. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Cosmai L; Gallieni M; Liguigli W; Porta C J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Takahashi S Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231 [TBL] [Abstract][Full Text] [Related]
11. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356 [TBL] [Abstract][Full Text] [Related]
12. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Underiner TL; Ruggeri B; Gingrich DE Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727 [TBL] [Abstract][Full Text] [Related]
13. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis. Liu S; Xin X; Hua T; Shi R; Chi S; Jin Z; Wang H PLoS One; 2016; 11(11):e0166658. PubMed ID: 27855197 [TBL] [Abstract][Full Text] [Related]
15. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Galvano A; Guarini A; Iacono F; Castiglia M; Rizzo S; Tarantini L; Gori S; Novo G; Bazan V; Russo A Expert Opin Drug Saf; 2019 Jun; 18(6):485-496. PubMed ID: 31062991 [TBL] [Abstract][Full Text] [Related]
16. [VEGF-receptor inhibitors for anti-angiogenesis]. Shibuya M Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004 [TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Sitohy B; Nagy JA; Dvorak HF Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695 [TBL] [Abstract][Full Text] [Related]
18. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo. Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Schenone S; Bondavalli F; Botta M Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703 [TBL] [Abstract][Full Text] [Related]